Barclays PLC Has $11.06 Million Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Barclays PLC grew its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 48.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 457,246 shares of the company's stock after acquiring an additional 148,883 shares during the quarter. Barclays PLC owned 0.21% of Hims & Hers Health worth $11,056,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its stake in Hims & Hers Health by 11.1% during the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after acquiring an additional 2,020,722 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after purchasing an additional 4,145,305 shares during the last quarter. Geode Capital Management LLC increased its position in Hims & Hers Health by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock valued at $104,724,000 after purchasing an additional 40,447 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Hims & Hers Health by 7.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company's stock valued at $43,448,000 after purchasing an additional 129,416 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on HIMS. Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Leerink Partners raised their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research report on Tuesday, February 25th. Bank of America boosted their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a report on Tuesday, March 18th. Truist Financial cut their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a report on Thursday, April 10th. Finally, Piper Sandler boosted their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a research report on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $38.08.

Hims & Hers Health Stock Down 0.2 %

NYSE HIMS traded down $0.05 on Friday, hitting $28.09. The stock had a trading volume of 12,141,328 shares, compared to its average volume of 15,545,291. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98. The company's 50-day moving average is $34.85 and its two-hundred day moving average is $30.84. The stock has a market cap of $6.24 billion, a price-to-earnings ratio of 63.67 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 3,236 shares of the business's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $27.77, for a total value of $89,863.72. Following the sale, the insider now owns 170,285 shares in the company, valued at approximately $4,728,814.45. The trade was a 1.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Irene Becklund sold 2,936 shares of the firm's stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $26.49, for a total transaction of $77,774.64. Following the completion of the transaction, the insider now directly owns 5,071 shares of the company's stock, valued at $134,330.79. This represents a 36.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 712,998 shares of company stock valued at $27,992,450. 17.71% of the stock is owned by insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.